Journal
BIOMEDICINE & PHARMACOTHERAPY
Volume 169, Issue -, Pages -Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2023.115877
Keywords
Breast cancer; DNA damage; BRCA1/2 mutation; PARP inhibitor; BRCAness
Ask authors/readers for more resources
DNA repair is an essential mechanism in cells for protecting against DNA damage. Dysfunctions in this repair pathway are closely associated with cancer development and progression, but also offer opportunities for targeted therapy. Recent research has focused on developing DNA repair inhibitors, such as PARP1 inhibitors, which have shown promising results in treating breast cancer. This review summarizes the research progress and clinical implementation of targeted treatments for the DNA repair pathway, specifically focusing on BRCA and BRCAness.
DNA repair is a vital mechanism in cells that protects against DNA damage caused by internal and external factors. It involves a network of signaling pathways that monitor and transmit damage signals, activating various cellular activities to repair DNA damage and maintain genomic integrity. Dysfunctions in this repair pathway are strongly associated with the development and progression of cancer. However, they also present an opportunity for targeted therapy in breast cancer. Extensive research has focused on developing inhibitors that play a crucial role in the signaling pathway of DNA repair, particularly due to the remarkable success of PARP1 inhibitors (PARPis) in treating breast cancer patients with BRCA1/2 mutations. In this review, we summarize the current research progress and clinical implementation of BRCA and BRCAness in targeted treatments for the DNA repair pathway. Additionally, we present advancements in diverse inhibitors of DNA repair, both as individual and combined approaches, for treating breast cancer. We also discuss the clinical application of DNA repair-targeted therapy for breast cancer, including the rationale, indications, and summarized clinical data for patients with different breast cancer subtypes. We assess their influence on cancer progression, survival rates, and major adverse reactions. Last, we anticipate forthcoming advancements in targeted therapy for cancer treatment and emphasize prospective areas of development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available